Your session is about to expire
← Back to Search
Other
An Alternative Way To Deliver Oxygen To People
Phase < 1
Waitlist Available
Led By Chris Bell, PhD
Research Sponsored by Christopher Bell
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up randomized crossover, visits separated by a minimum 7 days and maxim 14 days
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a new technology called Respirogen Micro-Oxygen (RMO) that delivers oxygen directly to the body through the rectum. The study focuses on healthy adults in low-oxygen environments to see how their bodies respond. This method could help people who have trouble breathing by providing oxygen without needing to inhale it.
Eligible Conditions
- Hypoxic Ventilatory Response
- Hypoxia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ randomized crossover, visits separated by a minimum 7 days and maxim 14 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~randomized crossover, visits separated by a minimum 7 days and maxim 14 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Increases Oxygen saturation (SpO2) with RMO
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Low Oxygen Visits with Respirogen Micro-OxygenExperimental Treatment1 Intervention
During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
Group II: Low Oxygen Visits without Respirogen Micro-OxygenActive Control1 Intervention
During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
Find a Location
Who is running the clinical trial?
Christopher BellLead Sponsor
8 Previous Clinical Trials
234 Total Patients Enrolled
Respirogen Inc.UNKNOWN
Chris Bell, PhDPrincipal InvestigatorCSU